X indening oral liquid improves cardiac function of rats with chronic cardiac failure via TGF-?1/Smad3 and p38 MAPK pathway

The expression of transforming growth factor-?1 (TGF-?1), drosophila mothers against decapentaplegic protein 3 (Smad3), and p38 mitogen activated protein kinase (p38 MAPK) were detected.Results: The results showed that Xin treatment significantly improved cardiac function but decreased the serum level of LDH, BNP, cTnI, and CKMB of CHF rats.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: Xindening oral liquid (Xin) is a widely used traditional Chinese medicine for the treatment of chronic heart failure (CHF).

📊

Key Findings & Data:Sixty male Wistar rats were randomly assigned to six groups 28 days after TAC: sham; CHF model; Xin at concentrations of 5 ml/kg, 10 mL/kg, and 20 mL/kg; and QiLi 0.6 g/kg.

💡

Conclusion & Impact:The expression of transforming growth factor-?1 (TGF-?1), drosophila mothers against decapentaplegic protein 3 (Smad3), and p38 mitogen activated protein kinase (p38 MAPK) were detected.Results: The results showed that Xin treatment significantly improved cardiac function but decreased the serum level of LDH, BNP, cTnI, and CKMB of CHF rats.

🔬Design:Modeling & Simulation

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objective: Xindening oral liquid (Xin) is a widely used traditional Chinese medicine for the treatment of chronic heart failure (CHF). However, the exact mechanisms related to its therapeutic effects against CHF remain unclear. In the present study, we investigate the effects of Xin on cardiac function in CHF rats and the possible mechanisms involved.Methods: Transverse aortic constriction (TAC) was conducted to induce a CHF rat model in this study. Sixty male Wistar rats were randomly assigned to six groups 28 days after TAC: sham; CHF model; Xin at concentrations of 5 ml/kg, 10 mL/kg, and 20 mL/kg; and QiLi 0.6 g/kg. After four weeks, the rats were treated with Xin (5, 10, or 20 mL/kg/d) for six weeks consecutively. At the end of the study, the cardiac function, heart weight index (HWI) and left ventricular mass index (LVMI), serum level of LDH, B-type natriuretic peptide (BNP), cTnI and CK-MB, and collagen volume fraction were studied. The expression of transforming growth factor-?1 (TGF-?1), drosophila mothers against decapentaplegic protein 3 (Smad3), and p38 mitogen activated protein kinase (p38 MAPK) were detected.Results: The results showed that Xin treatment significantly improved cardiac function but decreased the serum level of LDH, BNP, cTnI, and CKMB of CHF rats. In addition, it reduced the HWI, LVMI, and collagen volume fraction compared with the model group. Xin treatment significantly improved cardiac function and attenuated cardiac fibrosis by suppressing the p38 MAPK and TGF-?1/Smad3 signaling pathway in CHF rats.Conclusion: These results suggested that Xin might be a promising complementary treatment for CHF. More detailed experimental studies will be carried out in our subsequent research.

🔖

Cite This Article

WEİ, Y., GUO, C., ZHAO, J., YANG, J., Yİ, W., LIU, H., LİN, X., ZHANG, Z. (2017). X indening oral liquid improves cardiac function of rats with chronic cardiac failure via TGF-?1/Smad3 and p38 MAPK pathway. The Anatolian Journal of Cardiology, Cilt: 17 - Sayı: 5, 367–373. https://ajindex.com/articles/365381

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (9)

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: a re- port from the American Heart Association. Circulation 2012; 125: e2-e220. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Eze- kowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-44.
Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flax- man A, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014; 129: 1493-501.
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduga- nathan M, et al. The global health and economic burden of hospi- talizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-33.
Huffman MD, Prabhakaran D. Heart failure: epidemiology and pre- vention in India. Natl Med J India 2010; 23: 283-8.
MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Fin- layson A, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000; 102: 1126-31.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diag- nosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
Liu W, Chen J, Xu T, Tian W, Li Y, Zhang Z, et al. Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase. Am J Hypertens 2012; 25: 250-60.
Zou Y, Lin L, Ye Y, Wei J, Zhou N, Liang Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunc- tion during 4 weeks of pressure overload in mice. J Cardiovasc Pharmacol 2012; 59: 268-80.
Cui X, Zhang J, Li Y, Sun Y, Cao J, Zhao M, et al. Effects of Qili Qiangxin Capsule on AQP2, V2R, and AT1R in Rats with Chronic Heart Failure. Evid Based Complement Alternat Med 2015; 2015: 639450. Xiao H, Song Y, Li Y, Liao YH, Chen J. Qiliqiangxin regulates the bal- ance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction